.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,258,795

« Back to Dashboard
Patent 6,258,795 protects VISTOGARD and XURIDEN and is included in two NDAs.

This patent has one hundred and seventy-two patent family members in twenty-one countries.

Summary for Patent: 6,258,795

Title: Acylated uridine and cytidine and uses thereof
Abstract:The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal.
Inventor(s): von Borstel; Reid Warren (Darnestown, MD), Bamat; Michael Kevin (Darnestown, MD)
Assignee: Pro-Neuron, Inc. (Gaithersburg, MD)
Application Number:08/466,145
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYes6,258,795► subscribeY
Wellstat Therap
XURIDEN
uridine triacetate
GRANULE;ORAL208169-001Sep 4, 2015RXYes6,258,795► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,258,795

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,246,708 Methods for promoting wound healing with deoxyribonucleosides► subscribe
6,020,320 Acyl deoxyribonucleoside derivatives and uses thereof► subscribe
5,583,117 Acylated uridine and cytidine for elevating tissue uridine and cytidine► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,258,795

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria142221► subscribe
Austria179615► subscribe
Austria205850► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc